Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.63 |
| ▸ | LMNA | P02545 | 4/20 | 0.62 |
| ▸ | TSHR | P16473 | 3/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.62 |
| ▸ | THRB | P10828 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 3/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | IL1RN | P18510 | 1/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | MCOLN3 | Q8TDD5 | 2/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15652183 | 0.98 | ALDH1A1 (0.65) | ALDH1A1SMN1; SMN2LMNATSHRNPSR1 | |
| SCHEMBL27867187 | 0.87 | ALDH1A1 (0.61) | ALDH1A1SMN1; SMN2LMNATSHRNPSR1 | |
| SCHEMBL15651824 | 0.84 | PKM (0.56) | ALDH1A1SMN1; SMN2LMNATSHRNPSR1 | |
| SCHEMBL3343124 | 0.84 | ALDH1A1 (0.59) | ALDH1A1SMN1; SMN2LMNATSHRNPSR1 | |
| SCHEMBL29533339 | 0.84 | ALDH1A1 (0.59) | ALDH1A1SMN1; SMN2LMNATSHRNPSR1 | |
| SCHEMBL15650298 | 0.84 | POLB (0.61) | SMN1; SMN2LMNATSHRHTTGAA | |
| SCHEMBL29257268 | 0.82 | ALDH1A1 (0.45) | ALDH1A1SMN1; SMN2LMNATSHRNPSR1 | |
| SCHEMBL7363772 | 0.81 | CYP1A2 (0.47) | ALDH1A1SMN1; SMN2LMNATSHRNPSR1 | |
| SCHEMBL1002455 | 0.80 | ALDH1A1 (0.61) | ALDH1A1SMN1; SMN2LMNATSHRNPSR1 | |
| SCHEMBL1002454 | 0.80 | ALDH1A1 (0.61) | ALDH1A1SMN1; SMN2LMNATSHRNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104352492-B | Extend enzyme inhibitor using arylsulfonyl derivatives as the long chain fatty acids of active ingredient | MSD K.K.公司 | 2017-12-05 | — | — | CN | disclosed |
| CN-104352492-A | Long-chain fatty acyl elongase inhibitor comprising arylsulfonyl derivative as active ingredient | MSD KK | 2015-02-18 | — | — | CN | disclosed |
| EP-2280001-B1 | LONG-CHAIN FATTY ACID ELONGATION ENZYME INHIBITOR COMPRISING ARYLSULFONYL DERIVATIVE AS ACTIVE INGREDIENT | MSD KK (JP) | 2014-10-15 | — | — | EP | disclosed |
| US-8420823-B2 | Long-chain fatty acyl elongase inhibitor comprising arylsulfonyl derivative as active ingredient | MSD K.K. (JP) | 2013-04-16 | — | — | US | disclosed |
| US-8168673-B2 | Compounds having CRTH2 antagonist activity | OXAGEN LIMITED (GB) | 2012-05-01 | — | — | US | disclosed |
| EP-2280001-A1 | LONG-CHAIN FATTY ACID ELONGATION ENZYME INHIBITOR COMPRISING ARYLSULFONYL DERIVATIVE AS ACTIVE INGREDIENT | Banyu Pharmaceutical Co., Ltd. (JP) | 2011-02-02 | — | — | EP | disclosed |
| US-20110009622-A1 | LONG-CHAIN FATTY ACYL ELONGASE INHIBITOR COMPRISING ARYLSULFONYL DERIVATIVE AS ACTIVE INGREDIENT | MSD K.K. (JP) | 2011-01-13 | — | — | US | disclosed |
| EP-2240444-A1 | COMPOUNDS HAVING CRTH2 ANTAGONIST ACTIVITY | Oxagen Limited (GB) | 2010-10-20 | — | — | EP | disclosed |
| WO-2009093029-A1 | COMPOUNDS HAVING CRTH2 ANTAGONIST ACTIVITY | OXAGEN LIMITED (GB) | 2009-07-30 | — | — | WO | disclosed |
| US-20090192195-A1 | Compounds Having CRTH2 Antagonist Activity | OXAGEN LIMITED (GB) | 2009-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009622-A1 | LONG-CHAIN FATTY ACYL ELONGASE INHIBITOR COMPRISING ARYLSULFONYL DERIVATIVE AS ACTIVE INGREDIENT | ELOVL1, ELOVL6, ELOVL3 | ALDH1A1 188/4885SMN1; SMN2 965/4885LMNA 1767/4885 |
| US-20090192195-A1 | Compounds Having CRTH2 Antagonist Activity | HRH2, NR3C2, NR2C2 | ALDH1A1 3417/4885SMN1; SMN2 3524/4885LMNA 4029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.